Phase Ib expansion and dose optimization study of CX-5461 in patients with solid tumours enriched for DNA-repair deficiencies.
Ana Veneziani(Princess Margaret Cancer Centre), AM Oza(University Health Network), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Layla Mahmud(Ozmosis Research (Canada)), Minchun Chen(United States Military Academy), David W. Cescon(Princess Margaret Cancer Centre), Geoffrey Ira Shapiro(Dana-Farber Cancer Institute), Sarah E. Taylor(University of Pittsburgh Medical Center), Xiang Y. Ye(Princess Margaret Cancer Centre), Hyo S. Han(Moffitt Cancer Center), Paula Sliwo(Princess Margaret Cancer Centre), Diane M. Provencher(Centre Hospitalier de l’Université de Montréal), Lee S. Rosen, Yasmin Masalha(Ozmosis Research (Canada)), Pamela Denisse Soberanis Pina(Princess Margaret Cancer Centre), Stephanie Lheureux(University Health Network), Sagar D. Sardesai(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Valerie Bowering(University Health Network), Ping-Yen Huang(Electronic BioSciences (United States))
Cited by 0
Related Papers
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
|Nature|2002|1.2k
Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 <i>gag</i> Gene
|Journal of Virology|2003|398
Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag
|Journal of Virology|2005|265
Development of stable liquid formulations for adenovirus-based vaccines
|Journal of Pharmaceutical Sciences|2004|164